Skip to main content
Wiley Open Access Collection logoLink to Wiley Open Access Collection
. 2022 Sep 25;130(1):4–10. doi: 10.1111/1471-0528.17290

Weight gain during the menopause transition: Evidence for a mechanism dependent on protein leverage

Stephen J Simpson 1, David Raubenheimer 1, Kirsten I Black 2,3, Arthur D Conigrave 1,4,
PMCID: PMC10952331  PMID: 36073244

1. OVERVIEW

Progressive weight gain year‐on‐year, sufficient to drive significant increases in the prevalence of overweight and obesity, is a well‐recognised feature of the menopause transition, together with quantitatively smaller but similarly important losses of lean tissues, chiefly muscle and bone. However, the mechanisms that underlie these changes and the nature of the interactions between them have been unclear. Based on analysis of nutritional changes during the menopause transition we identify enhanced bodily protein breakdown as a putative trigger for weight gain via a mechanism known as the Protein Leverage Effect. It arises when progressive net bodily protein losses induce increased appetite for protein. If there is not a corresponding increase in the dietary protein concentration, the predicted consequence is excess non‐protein energy intake. Based on data from published clinical research studies, we show how weight gain and adiposity, as well as lean tissue losses, might be ameliorated or even prevented by a small adjustment upwards of 1–3% (digestible energy; DE) in dietary protein concentration, from around 16–17% DE if there is no change in physical activity, or to 19% DE if there is an accompanying reduction in physical activity of around 10%. In both cases the analysis predicts that an increase in dietary protein concentration can be achieved by making relatively small adjustments to the composition of the ‘standard daily menu’. The concept is provided in schematic form in Figure 1.

FIGURE 1.

FIGURE 1

Schematic diagram of the mechanism proposed for weight gain during the menopause transition.

2. HORMONAL FACTORS INTERACT WITH MACRONUTRIENT METABOLISM AND BODY COMPOSITION IN THE MENOPAUSE

Menopause arises from an age‐dependent loss of ovarian follicles and, in turn, a progressive failure of the endocrine mechanisms that support female fertility, dependent in part on the cyclical production of pituitary FSH and ovarian estrogens (see review 1 ). Along with the loss of menstrual periods, the menopause transition is marked by phenotypic changes including body weight gain associated with increased fat mass and decreased lean body mass associated with reduced skeletal muscle mass and net bone resorption. 2 , 3 , 4 The increase in body weight is sufficient to drive an age‐related increase in the prevalence of overweight and obesity. 5 In consequence, there are enhanced risks of cardiometabolic diseases, sarcopenia and osteoporosis. 4 , 6 , 7 Potentially important increases in regional adiposity have also been described in the menopause transition, including increased central adiposity 8 and increased cardiovascular fat depots, which contribute to the risk of coronary heart disease. 9

These medically important manifestations of the menopause, increased fat mass and reduced muscle and bone masses, can be explained if the primary hormonal changes described above produce, first, net protein breakdown and, second, increased dietary intake not only of protein but also of non‐protein energy to drive accumulation of fat stores. Two interacting mechanisms drive net protein breakdown in menopausal women: (i) enhanced protein breakdown, which is acutely reversible with estrogen replacement,10 and (ii) impaired protein synthesis, arising from anabolic resistance to dietary protein, which occurs in men as well as women and is associated with advancing age, 11 , 12 and in the context of delayed healing following certain muscle injuries (see review 13 ). Protein breakdown in the menopause transition arises, in part, from local increases in pro‐inflammatory cytokines, tumour necrosis factor (TNF)‐alpha and interleukin‐6. 14 , 15 , 16 Impaired protein synthesis, on the other hand, has been linked to impaired function of key mTOR pathways and is potentially amenable to strategies that promote the production of growth factors and/or stimulate growth factor receptor signalling pathways. 17 Only the former mechanism (i.e. enhanced protein breakdown in the context of estrogen withdrawal) would appear to be relevant to the present discussion relating to protein losses and an enhanced drive for protein intake and, in turn, energy intake during the menopause transition.

3. ENDOCRINE SIGNALS OF LOW PROTEIN STATES DRIVE PROTEIN APPETITE

Recent work has identified Fibroblast Growth Factor 21 (FGF21), a 181‐amino acid peptide synthesised primarily in the liver 18 but also in muscle, 19 as a hormonal signal of protein deficiency, which can be triggered by low protein intakes in both mice and humans. 20 , 21 , 22 , 23 One key effect of FGF21 whether delivered into the blood or the cerebrospinal fluid is to stimulate feeding and either promote a preference for foods that are high in protein concentration (%P) or induce increased consumption of a diet of a fixed %P. 24 Larson et al. described similar results, in which male mice injected intraperitoneally with FGF21 respectively increased and decreased their intakes of protein‐rich and carbohydrate‐rich foods 25 (see review 26 ). In both these studies, no change in total energy intake was observed when a choice of foods of different macronutrient compositions enabled increased protein intake without commensurately increasing energy intake. These findings are consistent with dietary studies demonstrating the existence of a protein‐specific appetite 27 , 28 , 29 , 30 and raise the possibility that the appetite response to enhanced protein breakdown in lean tissues and/or to reduced protein stores is also mediated by the prevailing plasma level of FGF21.

4. INTERACTION BETWEEN PROTEIN APPETITE AND FOODS WITH LOW PROTEIN CONCENTRATION—PROTEIN LEVERAGE

A specific appetite for protein dominates regulation of energy intake in many animals, humans included, when faced with nutritionally imbalanced diets—a phenomenon termed protein leverage. 31 Hence, when protein becomes diluted in the food supply by fats and carbohydrates, more energy is necessarily ingested in attaining the target intake of protein that signals satiety. Conversely, as protein becomes more concentrated in the diet, total energy intake is restricted. 32 Dilution of protein in the food supply has occurred progressively since World War 2, driven by the development and availability of mass‐produced, hyper‐palatable, energy‐dense, processed foods and beverages. 33 , 34 Such foods not only dilute protein in the food supply—their sensory characteristics (notably highly palatable combinations of sweet, fat, salt and umami flavours) also misdirect individuals' macronutrient selection towards lower‐protein foods. 35

Overconsumption of energy also arises from protein leverage if the requirement (‘regulatory intake target’) for protein increases but dietary protein density is unchanged relative to fat and carbohydrate. Protein requirements increase at times of anabolic demand (e.g. for growth and reproduction) or enhanced net protein breakdown, as described above for the menopause transition. In these circumstances, achieving a higher protein target without exceeding energy needs requires a change in macronutrient balance towards a higher percent protein diet. 31 , 32

5. GRAPHICAL MODEL OF HUMAN DATA: THE IMPACT OF INCREASED PROTEIN REQUIREMENTS ON ENERGY INTAKE

During the menopause transition, enhanced protein breakdown from lean tissues arising from estrogen loss and/or FSH excess, regardless of whether there are immediate lean tissue losses, is predicted to shift the regulatory targets for protein and energy, increasing the general target level for protein and, in some individuals, reducing energy needs. Unless the composition of the habitual diet changes towards a higher percent protein and exercise is maintained or increased, protein leverage drives excess energy intake, promoting overweight and its cardiometabolic consequences. The situation is exacerbated in individuals in whom there is reduced physical activity, which is positively associated with lean mass in menopausal women. 36

To explore the effects, we have developed a graphical model in two steps in Figure 2, based on nutritional geometry and values derived from the published literature. In Figure 2A, we consider an uncomplicated increase in protein requirements arising from net protein breakdown in muscle and bone. The black bullseye indicates hypothetical daily target intakes for protein and non‐protein energy prior to menopause. This combination (85 g protein and an energy intake of 2122 kcal (8.9 MJ), of which 1782 kcal (7.5 MJ) is in the form of non‐protein energy, i.e. carbohydrates and fats), represents a 16% DE protein diet (the black radial). The red bullseye provides an estimate of the shift required during the menopausal transition to a higher protein (91 g) target at the same total energy requirement of 2122 kcal (8.9 MJ). Attaining this new target requires a dietary shift to 17% DE protein (the red radial). However, were the individual to remain on a 16% DE protein diet, achieving her elevated protein intake requirement of 91 g per day would bring additional energy, an extra 153 kcal (0.64 MJ) per day (purple arrow).

FIGURE 2.

FIGURE 2

Graphical model describing the implications of the shift in protein and energy requirements during the menopause transition. See main text for a detailed explanation of the model. In brief, in (A) the black bullseye illustrates daily target intakes for protein and non‐protein energy prior to menopause. The red bullseye indicates an increased need for protein during the menopausal transition at the same total energy requirement. Simultaneously meeting the higher protein target while remaining in energy balance requires shifting to a higher percent protein diet (red radial). Remaining on the lower‐protein premenopausal diet requires increased energy intake to attain the higher protein target (purple arrow). (B) How this Protein Leverage Effect is exacerbated when the increased protein target is accompanied by reduced energy requirements due to a reduction in physical activity (review 4 , 45 ).

In Figure 2B, we consider a situation in which the increased protein target of 91 g is accompanied by a reduced energy target from 2122 to 1925 kcal (8.1 MJ) arising from a 9–10% reduction in physical activity. Achieving the increased protein target in this case requires a dietary shift to 19% DE protein; i.e. an increase of almost 20% above baseline. For an individual consuming protein at 1.0 g kg−1 day−1 this represents an increase to around 1.2 g kg−1 day−1. Were she to remain on a 16% DE protein diet, this would require an extra 360 kcal (1.5 mMJ) per day. Failure to increase energy intake on the existing 16% DE protein diet would lead to deficient protein intake, exacerbating lean mass loss, whereas consuming the extra 360 kcal would protect lean mass by achieving the increased protein target but risk weight gain, especially if accompanied by a reduction in physical activity (4). A combination in which the upwardly revised protein target is not achieved and there is ingestion of excess energy, risks both lean mass loss and weight gain.

6. PREDICTIONS FROM THE ANALYSIS

Four main predictions arise:

  1. There should be evidence of increased protein appetite.

Increased circulating FGF‐21 is a physiological indicator of elevated protein appetite in mammals 37 and is thus a candidate modulator of the response to tissue protein breakdown in the menopause. FGF‐21 levels rise with ageing in both sexes, a pattern exacerbated by protein catabolism in obesity and metabolic disease. 38 , 39 Peri‐menopausal women with overweight and metabolic syndrome exhibited elevated serum FGF‐21 levels compared with normal weight controls 40 and FGF‐21 levels were positively associated with atherosclerosis in postmenopausal women 41 , 42 but not in older Chinese men. 41 A similar sex‐specific association in relation to serum FGF‐21 and type 2 diabetes risk was reported in a mixed sex cohort (53% women; age 58 ± 6 SD years). 43 Serum FGF21 levels are also elevated in premenopausal women with obesity. 44

  • 2

    Lower dietary protein should be associated with elevated energy intakes and weight gain.

Postmenopausal women ingesting a higher‐protein diet (mean 18% DE) had lower fat mass and percent fat mass than those on a lower‐protein diet (mean 16% DE). 45 Although women on lower protein diets (<0.8 g kg−1 day−1; mean age 74 years) reported reduced energy ingestion 20–30 years postmenopause, 45 their overweight‐obese phenotype suggests inadequate exercise over a prolonged period and points to energy intakes during the menopause transition that were inappropriately high.

  • 3

    Weight gain and lean mass loss should be prevented by higher percent protein diets.

Low dietary protein intakes are associated with net lean mass loss in postmenopausal women. 46 In addition, in the context of energy restriction, high‐protein (30% DE) diets not only facilitated weight loss but were also more effective in preserving muscle/lean mass than moderate protein diets 47 , 48 , 49 (see review 50 ).

  • 4

    Higher percent protein diets should work synergistically with physical activity to stabilise lean mass and bone mineral density and prevent weight gain.

When an aerobic exercise programme was prescribed for premenopausal women (ages 19–45) in combination with a reduced energy, high‐ (30% DE) or standard‐ (15% DE) protein diet, fat mass decreased more markedly and lean mass increased in the high‐protein group. 51 In addition, protein supplementation augmented the positive effect of resistance training on skeletal muscle mass and performance in a meta‐analysis of 22 studies that included premenopausal and postmenopausal women. 52 The main points are presented in Box 1.

BOX 1. Main points.

  • The menopause transition increases individuals' susceptibilities to weight gain and obesity.

  • Protein requirements increase during the menopause transition due to tissue protein breakdown.

  • Increased protein breakdown is coupled to protein‐specific appetite by a mechanism based on production of FGF21 and/or other muscle or liver‐derived hormones.

  • The increase in protein appetite drives either a shift to foods with higher protein contents or increased total energy intake (protein leverage).

  • A failure to change the composition of the diet by the introduction of additional protein and removal of carbohydrate and/or fat results in increased energy intake and storage, and increased body weight.

  • A rational modification to the diet based on increased dietary protein concentration can be used to ameliorate or prevent weight gain.

7. TRANSLATIONAL IMPLICATIONS AND APPROACHES—A NEED FOR TARGETED FOOD EDUCATION

Based on the current state of knowledge, the following points seem reasonable. Women entering the menopause transition (around age 40–45) should be assessed for body weight, body mass index (BMI), cardiovascular health, lean body mass, skeletal health and musculoskeletal fitness. Diet and its composition should be assessed for total energy intake and protein concentration. Aerobic and resistance exercise schedules as well as general physical activity should be reviewed and new programmes developed as appropriate. Options for increasing dietary protein concentration should be provided and progress monitored. Dietary protein concentration should increase from a minimum of 16% DE (around 1.0 g kg−1) at age 40, to 18–20% DE (around 1.2 g kg−1) at age 50, and total energy intake should be reduced by around 10%, to ~8 MJ day−1. Removing ~250 kcal (1.0 MJ) per day of processed fats and carbohydrates lowers energy intake and increases percent protein and could help to solve the problem long‐term.

8. IMPLICATIONS FOR OSTEOPOROSIS AND SARCOPENIA

A detailed discussion of these issues is beyond the scope of the present analysis. Population level data for the menopause transition demonstrate there are significant lean tissue losses along with more substantial increases in fat mass. 3 This finding suggests that additional food intake, sufficient to drive enhanced adiposity and weight gain, is insufficient to overcome protein losses in muscle and bone in many women. In consequence, there are enhanced risks of sarcopenia and osteoporosis, as well as overweight and obesity, particularly with advancing age. Protein losses may arise if increased protein intake is insufficient to offset increased losses, as would be the case if the operation of the Protein Leverage Effect were incomplete (i.e. increased energy intake without fully satisfying the enhanced protein requirement). 32 In addition, partial anabolic resistance to dietary protein may impair muscle synthesis 11 and perhaps also bone protein synthesis in some women, even at relatively early stages of the menopause transition. Thus, increases in dietary protein concentration in the range revealed by our analysis (around 1–3% DE) may not only address the problem of increased energy intake but also, at least partially, overcome anabolic resistance and restore lean tissue masses. As anabolic resistance worsens with advancing age, further increases in protein intake may be required. 53 , 54 , 55 , 56

9. DISCUSSION WITH CONSUMERS

These matters were discussed in a 1‐hour session with six members of a women's consumer advisory group linked to the Community Menopause Service at Concord Hospital Sydney. Several of these women had sought advice on managing medical or health issues related to the menopause. There was immediate recognition of the problem: that a significant proportion of women undergoing the menopause transition report weight gain of 1–2 kg per year despite no changes in the foods they are eating or in the level of physical activity. However, the concern was expressed that many women would be unable to identify clearly low or high protein foods, suggesting the need for targeted education. This advice is consistent with the outcomes of a recent large study on ‘Protein Knowledge’ among older women and men. 57 Given the precise nature of the quantitative changes required in protein intake, this warrants particular attention.

10. DESIGNING A MODIFIED DIET TO PREVENT WEIGHT GAIN DURING THE MENOPAUSE TRANSITION AND TESTING ITS EFFECTIVENESS

The proposed intervention is a dietary modification alone that increases %P by 3% DE from the individual's baseline level, which is expected to increase total protein intake by 0.1–0.2 g kg−1 day−1, and lower total energy intake by 5–10%, i.e. by 6–12 kJ kg−1 day−1. The primary outcome measure will be body weight change with secondary outcome measures of fat and lean tissue masses by whole body DXA. The study will include women aged 40–50 years who have entered the menopause transition (variable duration of menstrual bleeding and/or intervals of amenorrhea ≥60 days) but are not yet postmenopausal (at least one menstrual period in the previous 12 months) with a BMI 18.5–29.5 kg m−2 and a habitual protein intake of 12–16% DE. Women meeting the inclusion criteria will be randomised to either (i) their normal diet with advice provided on healthy food options (control group) or (ii) the modified diet as described above (test group). The baseline level of physical activity will be determined by pedometry and monitored at 6‐monthly intervals over the course of the study. Study participants will be encouraged to maintain physical activity at current levels provided they are completing a minimum number of steps as informed by published studies. 58

Based on the expected size of the effect (0.5 kg body weight gain per year in controls; 0.5 kg body weight loss per year in subjects on the modified diet) we propose a 4‐year study with group sizes of 460 women in the control group and 460 women in the diet modification group (alpha 0.05, power 90%, drop‐out rate 20%). The number of participants required would fall if change in adiposity rather than change in body weight 3 is selected as the primary outcome measure. The study will also include 6‐monthly reviews of dietary intake, with renewed advice, as well as body weight determination and physical activity monitoring, together with annual measurements of whole body composition by DXA for adipose and lean tissue masses.

AUTHOR CONTRIBUTIONS

Prof. Stephen Simpson is Academic Director of the Charles Perkins Centre at the University of Sydney. He was responsible for the primary concept, established the overall plan for the write‐up, including key elements of the background literature search and discussion, undertook the modelling by nutritional geometry, and initiated the write‐up and was essential to its completion. Prof. David Raubenheimer is the Leonard P. Ullman Chair in Nutritional Ecology and leader of the Nutrition Theme at the Charles Perkins Centre. Prof. Raubenheimer co‐developed the primary concept, checked the results of the modelling by nutritional geometry, and contributed to all stages of the write‐up, including editing and proof‐reading. Prof. Kirsten Black is an academic gynaecologist at the University of Sydney, who leads the Menopause service at Concord Repatriation General Hospital. Prof. Black contributed to the development of the Protein Leverage concept for menopausal women, led the discussion of the findings and translational opportunities with a consumer group of menopausal women, and assisted with the write‐up, editing and proof‐reading. Prof. Em Arthur Conigrave is a Molecular and Clinical Endocrinologist based at the University of Sydney and Royal Prince Alfred Hospital. He developed the primary concept in the context of the major endocrine and metabolic changes of the menopause transition, established the proposed pathophysiological sequence of events, drafted several sections of the manuscript and took overall responsibility for editing, proof‐reading and article submission.

CONFLICT OF INTERESTS

None declared. Completed disclosure of interest forms are available to view online as supporting information.

DETAILS OF ETHICS APPROVAL

No human or animal approvals were required.

Supporting information

ICMJE

BJO-130-4-s001.docx (34.6KB, docx)

ICMJE

BJO-130-4-s002.docx (34.4KB, docx)

ICMJE

BJO-130-4-s004.docx (34.1KB, docx)

ICMJE

BJO-130-4-s003.docx (34.1KB, docx)

ACKNOWLEDGEMENTS

The authors would like to thank Sarah Carter (PhD student), who assisted with scheduling and facilitating the discussion with members of a women's consumer advisory group. Open access publishing facilitated by The University of Sydney, as part of the Wiley – The University of Sydney agreement via the Council of Australian University Librarians.

Simpson SJ, Raubenheimer D, Black KI, Conigrave AD. Weight gain during the menopause transition: Evidence for a mechanism dependent on protein leverage. BJOG. 2023;130(1):4–10. 10.1111/1471-0528.17290

DATA AVAILABILITY STATEMENT

Data sharing not applicable ‐ no new data generated.

REFERENCES

  • 1. Nelson H. Menopause. Lancet. 2008;371:760–70. [DOI] [PubMed] [Google Scholar]
  • 2. Hodson L, Harnden K, Banerjee R, Real B, Marinou K, Karpe F, et al. Lower resting and total energy expenditure in postmenopausal compared with premenopausal women matched for abdominal obesity. J Nutr Sci. 2014;3:e3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3. Greendale GA, Sternfeld B, Huang M, Han W, Karvonen‐Gutierrez C, Ruppert K, et al. Changes in body composition and weight during the menopause transition. JCI Insight. 2019;4:e124865. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4. Lovejoy J, Champagne C, de Jonge L, Xie H, Smith S. Increased visceral fat and decreased energy expenditure during the menopausal transition. Int J Obes (Lond). 2008;32:949–58. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5. Flegal K, Kruszon‐Moran D, Carroll M, Fryar C, Ogden C. Trends in obesity among adults in the United States, 2005 to 2014. JAMA. 2016;315:2284–91. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6. Poehlman E, Tchernof A. Traversing the menopause: changes in energy expenditure and body composition. Coron Artery Dis. 1998;9:799–803. [PubMed] [Google Scholar]
  • 7. Stefanska A, Bergmann K, Sypniewska G. Metabolic syndrome and menopause: pathophysiology, clinical and diagnostic significance. Adv Clin Chem. 2015;72:1–75. [DOI] [PubMed] [Google Scholar]
  • 8. Sternfeld B, Wang H, Quesenberry CP, Abrams B, Everson‐Rose SA, Greendale GA, et al. Physical activity and changes in weight and waist circumference in midlife women: findings from the study of Women's Health Across the Nation. Am J Epidemiol. 2004;160:912–22. [DOI] [PubMed] [Google Scholar]
  • 9. Hanley C, Matthews KA, Brooks MM, Janssen I, Budoff MJ, Sekikawa A, et al. Cardiovascular fat in women in midlife: effects of race, overall adiposity, and central adiposity. The SWAN Cardiovascular Fat Study. Menopause. 2017;25:38–45. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10. Park YM, Keller AC, Runchey SS, Miller BF, Kohrt WM, Van Pelt RE, et al. Acute estradiol treatment reduces skeletal muscle protein breakdown markers in early‐ but not late‐postmenopausal women. Steroids. 2019;146:43–9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11. Wilkinson D, Piasecki M, Atherton P. The age‐related loss of skeletal muscle mass and function: Measurement and physiology of muscle fibre atrophy and muscle fibre loss in humans. Ageing Res Rev. 2018;47:123–32. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12. Hodson N, West D, Philp A, Burd N, Moore D. Molecular recognition of human skeletal muscle protein synthesis in response to exercise and nutrients: a compass for overcoming age‐related anabolic resistance. Am J Physiol Cell Physiol. 2019;317:C1061–78. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13. Tipton K. Nutritional support for exercise‐induced injuries. Sports Med. 2015;45:S93–104. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14. Park Y, Jankowski C, Ozemek C, Hildreth K, Kohrt W, Moreau K. Appendicular lean mass is lower in late compared with early perimenopausal women: potential role of FSH. J Appl Physiol. 2020;128:1373–80. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15. Uehara I, Soldi L, Silva M. Current perspectives of osteoclastogenesis through estrogen modulated immune cell cytokines. Life Sci. 2020;256:117921. [DOI] [PubMed] [Google Scholar]
  • 16. Geraci A, Calvani R, Ferri E, Marzetti E, Arosio B, Cesari M. Sarcopenia and menopause: the role of estradiol. Front Endocrinol. 2021;12:682012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17. Agostini D, Donati SZ, Lucertini F, Annibalini G, Gervasi M, Marini CF, et al. Muscle and bone health in postmenopausal women: role of protein and vitamin D supplementation combined with exercise training. Nutrients. 2018;10:1103. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18. Nishimura T, Nakatake Y, Konishi M, Itoh N. Identification of a novel FGF, FGF‐21, preferentially expressed in the liver. Biochim Biophys Acta. 2000;1492:203–6. [DOI] [PubMed] [Google Scholar]
  • 19. Ribas F, Villarroya J, Hondares E, Giralt M, Villarroya F. FGF21 expression and release in muscle cells: involvement of MyoD and regulation by mitochondria‐driven signalling. Biochem J. 2014;463:191–9. [DOI] [PubMed] [Google Scholar]
  • 20. Laeger T, Henagan T, Albarado D, Redman L, Bray G, Noland R, et al. FGF21 is an endocrine signal of protein restriction. J Clin Invest. 2014;124:3913–22. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21. Solon‐Biet S, Cogger V, Pulpitel T, Heblinski M, Wahl D, McMahon A, et al. Defining the nutritional and metabolic context of FGF21 using the geometric framework. Cell Metab. 2016;24:555–65. [DOI] [PubMed] [Google Scholar]
  • 22. Gosby A, Lau N, Tam C, Iglesias M, Morrison C, Caterson I, et al. Raised FGF‐21 and triglycerides accompany increased energy intake driven by protein leverage in lean, healthy individuals: a randomised trial. PLoS One. 2016;11:e0161003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23. Hill C, Berthoud H, Münzberg H, Morrison C. Homeostatic sensing of dietary protein restriction: a case for FGF21. Front Neuroendocrinol. 2018;51:125–31. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24. Hill C, Laeger T, Dehner M, Albarado D, Clarke B, Wanders D, et al. FGF21 signals protein status to the brain and adaptively regulates food choice and metabolism. Cell Rep. 2019;27:2934–47. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25. Larson KR, Chaffin AT, Goodson ML, Fang Y, Ryan KR. Fibroblast Growth Factor‐21 controls dietary protein intake in male mice. Endocrinology. 2019;160:1069–80. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26. Wu C, Chaffin AT, Ryan KK. Fibroblast Growth Factor 21 facilitates the homeostatic control of feeding behavior. J Clin Med. 2022;11:580. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27. Dibattista D, Holder MD. Enhanced preference for a protein‐containing diet in response to dietary protein restriction. Appetite. 1998;30:237–54. [DOI] [PubMed] [Google Scholar]
  • 28. White B, Porter M, Martin R. Protein selection, food intake, and body composition in response to the amount of dietary protein. Physiol Behav. 2000;69:383–9. [DOI] [PubMed] [Google Scholar]
  • 29. Murphy M, Peters K, Denton B, Lee K, Chadchankar H, McCutcheon J. Restriction of dietary protein leads to conditioned protein preference and elevated palatability of protein‐containing food in rats. Physiol Behav. 2018;184:235–41. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30. Tomé D, Chaumontet C, Even P, Darcel N, Azzout‐Marniche D. Protein status modulates the rewarding value of foods and meals to maintain an adequate protein intake. Physiol Behav. 2019;206:7–12. [DOI] [PubMed] [Google Scholar]
  • 31. Simpson S, Raubenheimer D. Obesity: the protein leverage hypothesis. Obes Rev. 2005;6:133–42. [DOI] [PubMed] [Google Scholar]
  • 32. Raubenheimer D, Simpson S. Protein leverage: theoretical foundations and ten points of clarification. Obesity. 2019;27:1225–38. [DOI] [PubMed] [Google Scholar]
  • 33. Martínez Steele E, Raubenheimer D, Simpson S, Baraldi L, Monteiro C. Ultra‐processed foods, protein leverage and energy intake in the USA. Public Health Nutr. 2018;21:114–24. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34. Hall K, Ayuketah A, Brychta R, Cai H, Cassimatis T, Chen K, et al. Ultra‐processed diets cause excess calorie intake and weight gain: an inpatient randomized controlled trial of ad libitum food intake. Cell Metab. 2019;30:67–77. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35. Simpson SJ, Raubenheimer D. Perspective: Tricks of the trade. Nature. 2014;508:S66. [DOI] [PubMed] [Google Scholar]
  • 36. Martinez JA, Wertheim BC, Thomson CA, Bea JW, Wallace R, Allison M, et al. Physical activity modifies the association between dietary protein and lean mass of postmenopausal women. J Acad Nutr Diet. 2016;117:119–203. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37. Hill C, Qualls‐Creekmore E, Berthoud H, Soto P, Yu S, McDougal D, et al. FGF21 and the physiological regulation of macronutrient preference. Endocrinology. 2020;161:bqaa019. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38. Hanks L, Casazza K, Ashraf A, Wallace S, Gutiérrez O. Fibroblast growth factor‐21, body composition, and insulin resistance in pre‐pubertal and early pubertal males and females. Clin Endocrinol (Oxf). 2015;82:550–6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39. Phillips S, Paddon‐Jones D, Layman D. Optimizing adult protein intake during catabolic health conditions. Adv Nutr. 2020;11:S1058–S69. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40. Palla G, Ramírez‐Morán C, Montt‐Guevara M, Salazar‐Pousada D, Shortrede J, Simoncini T, et al. Perimenopause, body fat, metabolism and menopausal symptoms in relation to serum markers of adiposity, inflammation and digestive metabolism. J Endocrinol Invest. 2020;43:809–20. [DOI] [PubMed] [Google Scholar]
  • 41. Chow W, Xu A, Woo Y, Tso A, Cheung S, Fong C, et al. Serum fibroblast growth factor‐21 levels are associated with carotid atherosclerosis independent of established cardiovascular risk factors. Arterioscler Thromb Vasc Biol. 2013;33:2454–9. [DOI] [PubMed] [Google Scholar]
  • 42. Basurto L, Gregory M, Hernández S, Sánchez‐Huerta L, Martínez A, Manuel‐Apolinar L, et al. Monocyte chemoattractant protein‐1 (MCP‐1) and fibroblast growth factor‐21 (FGF‐21) as biomarkers of subclinical atherosclerosis in women. Exp Gerontol. 2019;124:110624. [DOI] [PubMed] [Google Scholar]
  • 43. Wang Y, Ye J, Cao Y, Zhang R, Liu Y, Zhang S, et al. Increased serum/plasma fibroblast growth factor 21 in type 2 diabetes mellitus: a systematic review and meta‐analysis. Postgrad Med J. 2019;95:134–9. [DOI] [PubMed] [Google Scholar]
  • 44. Akyildiz Z, Polat S, Yurekli B, Kocabas G, Tuluce K, Tuluce S, et al. Epicardial fat, body mass index, and triglyceride are independent contributors of serum fibroblast growth factor 21 level in obese premenopausal women. J Endocrinol Invest. 2015;38:361–6. [DOI] [PubMed] [Google Scholar]
  • 45. Gregorio L, Brindisi J, Kleppinger A, Sullivan R, Mangano K, Bihuniak J, et al. Adequate dietary protein is associated with better physical performance among post‐menopausal women 60‐90 years. J Nutr Health Aging. 2014;18:155–60. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46. Bopp M, Houston D, Lenchik L, Easter L, Kritchevsky S, Nicklas B. Lean mass loss is associated with low protein intake during dietary‐induced weight loss in postmenopausal women. J Am Diet Assoc. 2008;108:1216–20. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47. Gordon M, Bopp M, Easter L, Miller G, Lyles M, Houston D, et al. Effects of dietary protein on the composition of weight loss in post‐menopausal women. J Nutr Health Aging. 2008;12:505–9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48. Campbell W, Tang M. Protein intake, weight loss, and bone mineral density in postmenopausal women. J Gerontol A Biol Sci Med Sci. 2010;65:1115–22. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49. Smith G, Commean P, Reeds D, Klein S, Mittendorfer B. Effect of protein supplementation during diet‐induced weight loss on muscle mass and strength: a randomized controlled study. Obesity. 2018;26:854–61. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50. Varady K. Dietary strategies for weight loss in midlife women. Menopause. 2018;25:697–9. [DOI] [PubMed] [Google Scholar]
  • 51. Josse A, Atkinson S, Tarnopolsky M, Phillips S. Increased consumption of dairy foods and protein during diet‐ and exercise‐induced weight loss promotes fat mass loss and lean mass gain in overweight and obese premenopausal women. J Nutr. 2011;141:1626–34. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52. Cermak N, Res P, de Groot L, Saris W, van Loon L. Protein supplementation augments the adaptive response of skeletal muscle to resistance‐type exercise training: a meta‐analysis. Am J Clin Nutr. 2012;96:1454–64. [DOI] [PubMed] [Google Scholar]
  • 53. Moore D, Churchward‐Venne T, Witard O, Breen L, Burd N, Tipton K, et al. Protein ingestion to stimulate myofibrillar protein synthesis requires greater relative protein intakes in healthy older versus younger men. J Gerontol A Biol Sci Med Sci. 2015;70:57–62. [DOI] [PubMed] [Google Scholar]
  • 54. Kerstetter JE, Bihuniak JD, Brindisi J, Sullivan RR, Mangano KM, Larocque S, et al. The effect of a whey protein supplement on bone mass in older caucasian adults. J Clin Endocrinol Metab. 2015;100:2214–22. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55. Rizzoli R, Biver E, Brennan‐Speranza TC. Nutritional intake and bone health. Lancet Diabetes Endocrinol. 2021;9:606–21. [DOI] [PubMed] [Google Scholar]
  • 56. Hengeveld L, de Goede J, Afman L, Bakker S, Beulens J, Blaak E, et al. Health effects of increasing protein intake above the current population reference intake in older adults: a systematic review of the health council of The Netherlands. Adv Nutr. 2021;13(4):1083–117. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57. Visser M, Hung Y, Verbeke W. Protein knowledge of older adults and idenitification of subgroups with poor knowledge. Nutrients. 2021;13:1006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58. Silva TR, Spritzer PM. Skeletal muscle mass is associated with higher dietary protein intake and lower body fat in postmenopausal women: a cross‐sectional study. Menopause. 2016;24:502–9. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

ICMJE

BJO-130-4-s001.docx (34.6KB, docx)

ICMJE

BJO-130-4-s002.docx (34.4KB, docx)

ICMJE

BJO-130-4-s004.docx (34.1KB, docx)

ICMJE

BJO-130-4-s003.docx (34.1KB, docx)

Data Availability Statement

Data sharing not applicable ‐ no new data generated.


Articles from Bjog are provided here courtesy of Wiley

RESOURCES